Navigation Links
RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109
Date:6/6/2013

WESTBOROUGH, Mass., June 6, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQB: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today  announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA® compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor (CTGF). Over-expression of this protein in wounds has been associated with abnormal scarring as seen in hypertrophic scars and keloids.

"Based on the animal data, we were confident that RXI-109 would not cause significant side effects or toxicities in this first study, and we are pleased to announce that confirmation today," said Dr. Geert Cauwenbergh , President and CEO of RXi Pharmaceuticals. He added that: "It is remarkable and a great outcome that we have also been able to get a good read-out on a key biomarker for scarring in this study. Indeed, almost 3 months after a single intradermal dose of RXI-109, histological comparisons between the drug- and placebo-treated sites in the volunteers showed that RXI-109 significantly reduced the expression of CTGF in the wound area in a dose dependent manner, suggesting a potent and long lasting effect on this key biomarker for abnormal scarring. We look forward to having the unblinded results of our second Phase 1 trial, with multiple doses of RXI-109, available for our Investor and Analyst Symposium  on July 12, 2013."

About the study

In this first Phase 1 study, 15 volunteers with no known predisposition for abnormal scarring were treated in 5 cohorts. Each subject received a single intradermal injection of RXI-109 in two small 2-cm areas of the abdomen. Two identical areas
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaceuticals Market Access Taiwan 2013
2. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
3. Isis Pharmaceuticals to Present at the Goldman Sachs 34th Annual Global Healthcare Conference
4. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
5. Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer
6. Ferring Pharmaceuticals Inc. Announces $1M Donation to the Alliance for Fertility Preservation, a Newly Formed Charitable Organization
7. Ampio Pharmaceuticals Provides Clinical Updates
8. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
9. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
10. Isis Pharmaceuticals Announces Exercise of Underwriters Option to Purchase Additional Shares
11. Vanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ga. and RALEIGH, N.C. ... Trial Marketing Communications, LLC (CTMC), and Integrated Clinical ... patient recruitment and retention for clinical trials announce ... Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS will ... retention services to pharmaceutical, biotechnology and medical device ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
(Date:12/15/2014)... --Research and Markets , ... announced the addition of the "Cardiac Guidewires - ... offering. Global Guidewires sector is projected to reach ... accounts for nearly 35% (2015) of the ... approximately 25% (2018). Asia-Pacific is ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... Broadest, Most Comprehensive Survey Provides New Benchmark on MRSA,in Healthcare ... today by APIC: , , WHAT:, ... Methicillin-resistant, Staphylococcus aureus (MRSA), ... in U.S. healthcare facilities., -- MRSA ...
... LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc.,(OTCBB:NRGX) ... issue,of the journal The Lancet of positive results ... disease and the first report of,direct gene transfer ... adult,neurodegenerative disease., The open label Phase 1 study, ...
Cached Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:12/19/2014)... Dennis Thompson HealthDay ... -- Ebola,s entrance into the United States -- along ... mumps outbreak -- have highlighted cracks in the nation,s ... new health policy report released Thursday. Half of ... respond to infectious disease outbreaks. That was the main ...
(Date:12/19/2014)... 2014 Hands On Mobile Spa, has announced ... Spa On Wheels has been transformed into a utopia for ... world seems to disappear. The Virtual Tour showcases the beauty ... parties, corporate events and more. , The Virtual Tour shows ... which is actually an overhauled Winnebago. Marla Kaplan-Pelle, Director states ...
(Date:12/19/2014)... Wisconsin (PRWEB) December 19, 2014 After ... music performer is again returning to the stage to ... her husband for concert performances, and the successful tour ... was originally announced. , Visit Ticketability.com ... the newly-announced Detroit shows at fair prices. , Music ...
(Date:12/19/2014)... (HealthDay News) -- A new study suggests a possible ... hot flashes and night sweats -- and higher rates ... are common during menopause, affecting about 60 percent of ... after menopause, since they then face a higher risk ... women who exhibit moderate or severe menopausal symptoms are ...
(Date:12/19/2014)... Prostaglandin analogue eye drops -- a common form of ... loss in patients with the eye disease, a new ... of the Moorfields Eye Hospital and UCL Institute of ... people newly diagnosed with open-angle glaucoma -- the most ... leading causes of blindness. About 45 million people ...
Breaking Medicine News(10 mins):Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2
... 2 (HealthDay News) -- Babies born to women who smoke ... have a congenital heart defect than are the offspring of ... increased risk ranged from 20 percent to 70 percent, varying ... that obstruct the flow of blood from the right side ...
... long-term alcohol abuse is detrimental to memory function and ... published in Age and Ageing by Oxford ... consumption may decrease the risk of cognitive decline or ... the prevalence of alcohol-related dementia to be about 10% ...
... 18th Conference on Retroviruses and Opportunistic Infections is ... from February 27 through March 2. Day three of ... presentations from scientists supported by the National Institute of ... Institutes of Health. iPrEx Update , ...
... By Amanda Gardner HealthDay Reporter , TUESDAY, March 1 ... announcement Monday that researchers reconfigured immune cells so that they became ... But they say the jury is out on whether the ... is ultimately a cure or what,s called a "functional cure" -- ...
... years are a critical period for addressing weight-related ... University of Illinois at Chicago. Among young children, ... is highest among black and Hispanic children. ... from the U.S. Department of Agriculture to integrate ...
... Eye Institute (NEI) and Food and Drug Administration (FDA) ... endpoints for clinical trials of visual prostheses will be ... visual fields and contrast sensitivity. These assessments may provide ... Today, functional vision outcomes such as ...
Cached Medicine News:Health News:Smoking During Early Pregnancy May Put Baby's Heart at Risk 2Health News:Research suggests alcohol consumption helps stave off dementia 2Health News:Research suggests alcohol consumption helps stave off dementia 3Health News:CROI -- Day 3: Selected highlights of NIH-supported research 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 2Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 3Health News:Gene Therapy Against HIV Not a Proven Cure, Experts Say 4Health News:$1 million USDA grant aims to reduce obesity in preschoolers 2Health News:Visual prostheses: Symposium to explore combining functional endpoints 2
A convenient, rotating standholds up to seven Gilson pipettes (any model) with exceptional stability. Protects your precious pipettes from possible damage or contamination....
... Tracker is an automated solution for scheduling, ... performance testing for all pipettes and liquid ... any balance Supports all gravimetric ... DIN 12650, ISO 9000, NCCLS and GLP ...
... bottom allows easy withdrawal of solution ,• ... ,• Corner pouring lips facilitate pour-out ... for 4, 8, and 12 channel ... withdrawal of practically all of the solution. ...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile...
Medicine Products: